INKEF Capital

Founded 2010


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 57
Average round size
The average size of a deal this fund participated in
Portfolio companies 41
Rounds per year 5.18
Lead investments 30
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 6
Key employees 8
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Software
  • Medical Device
  • Medical

In 2010 was created INKEF Capital, which is appeared as VC. The leading representative office of defined VC is situated in the Amsterdam. The company was established in Europe in The Netherlands.

The overall number of key employees were 7.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the INKEF Capital, startups are often financed by Union Square Ventures, Life Sciences Partners, Index Ventures. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Healthinnovations, Gilde Healthcare. In the next rounds fund is usually obtained by Keen Venture Partners, Union Square Ventures, Rabobank.

The top amount of exits for fund were in 2018. The real fund results show that this VC is 48 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this INKEF Capital performs on 15 percentage points less the average number of lead investments. The high activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.

The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Health Care, Biopharma. For fund there is a match between the location of its establishment and the land of its numerous investments - The Netherlands. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight NMD Pharma, Rainier Therapeutics, Shapeways.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


3D Printing
Business/Productivity Software
Multimedia and Design Software
Peer to Peer
$75M30 Sep 2021 New York, New York, United States


Artificial Intelligence
Financial Services
Information Technology
$6M02 Jun 2021 Amsterdam, North Holland, Netherlands


Health Care
Medical Device
$31M22 Apr 2021 Eindhoven, North Brabant, Netherlands


Information Technology
Retail Technology
$5M19 Jan 2021 Leiden, South Holland, Netherlands


Cyber Security
Fraud Detection
Risk Management
$23M01 Dec 2020 Amsterdam, North Holland, Netherlands


Financial Services
Information Technology
$3M22 Oct 2020 Amsterdam, North Holland, Netherlands


Cyber Security
Fraud Detection
Risk Management
$23M22 Sep 2020 Amsterdam, North Holland, Netherlands


Health Care
Medical Device
$11M08 Jul 2020 Utrecht, Utrecht, Netherlands


Cloud Computing
Human Resources
Online Portals
$12M20 May 2020 Helsinki, Uusimaa, Finland
Cardior Raises €64M in Series B Funding

– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.

Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives

– Castor, a leading provider of clinical trial software, announced the closing of a $45m Series B financing round.
– The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.
– Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent INKEF Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: